PL369827A1 - Zastosowanie podstawionych aminometylochromanów wleczeniu zaburzeń ruchu - Google Patents

Zastosowanie podstawionych aminometylochromanów wleczeniu zaburzeń ruchu

Info

Publication number
PL369827A1
PL369827A1 PL02369827A PL36982702A PL369827A1 PL 369827 A1 PL369827 A1 PL 369827A1 PL 02369827 A PL02369827 A PL 02369827A PL 36982702 A PL36982702 A PL 36982702A PL 369827 A1 PL369827 A1 PL 369827A1
Authority
PL
Poland
Prior art keywords
treatment
movement disorders
substituted aminomethyl
aminomethyl chromans
chromans
Prior art date
Application number
PL02369827A
Other languages
English (en)
Other versions
PL207146B1 (pl
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Henning Böttcher
Heinz-Hermann Bokel
Uschi Schmid-Grossmann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL369827A1 publication Critical patent/PL369827A1/pl
Publication of PL207146B1 publication Critical patent/PL207146B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL369827A 2001-09-12 2002-08-09 Zastosowanie podstawionych aminometylochromanów w terapii ubocznych efektów działania leków stosowanych w idiopatycznej chorobie Parkinsona lub chorobie Parkinsona w przypadku zespołu Parkinsona i/lub w leczeniu pozapiramidalnych objawów wywołanych przez neuroleptyki oraz zawierająca je kompozycja farmaceutyczna PL207146B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01121910 2001-09-12

Publications (2)

Publication Number Publication Date
PL369827A1 true PL369827A1 (pl) 2005-05-02
PL207146B1 PL207146B1 (pl) 2010-11-30

Family

ID=8178618

Family Applications (1)

Application Number Title Priority Date Filing Date
PL369827A PL207146B1 (pl) 2001-09-12 2002-08-09 Zastosowanie podstawionych aminometylochromanów w terapii ubocznych efektów działania leków stosowanych w idiopatycznej chorobie Parkinsona lub chorobie Parkinsona w przypadku zespołu Parkinsona i/lub w leczeniu pozapiramidalnych objawów wywołanych przez neuroleptyki oraz zawierająca je kompozycja farmaceutyczna

Country Status (23)

Country Link
US (1) US20040235920A1 (pl)
EP (1) EP1425008B1 (pl)
JP (1) JP2005522410A (pl)
KR (1) KR100886185B1 (pl)
CN (1) CN1303996C (pl)
AR (1) AR036509A1 (pl)
AT (1) ATE341322T1 (pl)
AU (1) AU2002331220B2 (pl)
BR (1) BR0212199A (pl)
CA (1) CA2458628A1 (pl)
CY (1) CY1105868T1 (pl)
DE (1) DE60215203T2 (pl)
DK (1) DK1425008T3 (pl)
ES (1) ES2272771T3 (pl)
HU (1) HUP0401317A3 (pl)
MX (1) MXPA04002304A (pl)
MY (1) MY130522A (pl)
PL (1) PL207146B1 (pl)
PT (1) PT1425008E (pl)
RU (1) RU2320336C2 (pl)
SI (1) SI1425008T1 (pl)
WO (1) WO2003022269A1 (pl)
ZA (1) ZA200402774B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003254282A1 (en) 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
CN101120002A (zh) 2005-02-17 2008-02-06 惠氏公司 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物
KR101825972B1 (ko) * 2010-10-15 2018-02-06 콘테라 파르마 에이피에스 운동 장애 치료를 위한 세로토닌 수용체 작용제의 조합

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE9303274D0 (sv) * 1993-10-07 1993-10-07 Astra Ab Novel phenylethyl and phenylproplamines
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE10101917A1 (de) 2001-01-16 2002-07-18 Bayer Ag Verwendung von Chromanen

Also Published As

Publication number Publication date
DK1425008T3 (da) 2007-01-15
CN1303996C (zh) 2007-03-14
DE60215203D1 (de) 2006-11-16
KR100886185B1 (ko) 2009-02-27
ES2272771T3 (es) 2007-05-01
US20040235920A1 (en) 2004-11-25
KR20040043175A (ko) 2004-05-22
EP1425008A1 (en) 2004-06-09
CY1105868T1 (el) 2011-02-02
HUP0401317A2 (en) 2004-10-28
DE60215203T2 (de) 2007-10-18
MXPA04002304A (es) 2004-06-29
RU2320336C2 (ru) 2008-03-27
ZA200402774B (en) 2005-01-13
PT1425008E (pt) 2007-01-31
AR036509A1 (es) 2004-09-15
MY130522A (en) 2007-06-29
AU2002331220B2 (en) 2007-06-07
EP1425008B1 (en) 2006-10-04
SI1425008T1 (sl) 2007-02-28
WO2003022269A1 (en) 2003-03-20
BR0212199A (pt) 2004-10-05
HUP0401317A3 (en) 2007-05-29
CN1555259A (zh) 2004-12-15
ATE341322T1 (de) 2006-10-15
RU2004111284A (ru) 2005-05-10
CA2458628A1 (en) 2003-03-20
PL207146B1 (pl) 2010-11-30
JP2005522410A (ja) 2005-07-28

Similar Documents

Publication Publication Date Title
IL209842A0 (en) Compounds for the treatment of metabolic disorders
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
ZA200401004B (en) Combination for the treatment of inflammatory disorders
SI1474416T1 (sl) Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj
AU4256801A (en) Treatment of movement disorders
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
PL373626A1 (pl) Leczenie zaburzeń centralnego układu nerwowego
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
EP1581209A4 (en) NEW BENZOPYRAN ANALOGUE AND ITS USE FOR THE TREATMENT OF GLAUKOM
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
SI1427724T1 (sl) Nova uporaba substituiranih aminometil-kromanov
IL162053A0 (en) Method for the treatment of bone disorders
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
GB0125371D0 (en) Treatment of movement disorders
SI1425008T1 (sl) Uporaba substituiranih aminometilkromanov za zdravljenje stranskih ucinkov nevroleptikov
GB0213575D0 (en) Treatment for movement disorders
GB0017951D0 (en) Treatment of movement disorders
AU2001223867A1 (en) Composition containing flavonoids for treatment brain disorders

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20110809